Neuroprotection in stroke.
Stroke is the leading cause of death and disability worldwide. rt-PA is the approved drug and its use is restricted only to the first 3-4.5 hours of stroke. The review focuses on key events during early stages of ischaemic stroke and on pathogenic roles of distinctive molecules and metabolic pathways that compromise cell survival and affect infarct progression. An overview of various neuroprotective strategies is presented in this article.